Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide in Adult Participants With IBS-D
NCT07545759Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing LY3537031 with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days. Started May 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07545759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545759.